If the CFO is wrong in his statements there might not be a job for him to keep. GILD went way out on a limb with the $11B purchase of VRUS and I am wondering if that will kill the company. Between the loss of their HIV monopoly to generics and the lack of a sustainable HCV population, how will they maintain their $8B revenue stream.
There’s no possibility of punitive action against GILD’s CFO because what she said about the GS-7977 IP was somewhat subjective and was not clearly contradictory to the warnings in GILD’s 10-Q filing.
Market Data 
Markets 
AI
